vs
Side-by-side financial comparison of EXELIXIS, INC. (EXEL) and SCANSOURCE, INC. (SCSC). Click either name above to swap in a different company.
SCANSOURCE, INC. is the larger business by last-quarter revenue ($766.5M vs $598.7M, roughly 1.3× EXELIXIS, INC.). EXELIXIS, INC. runs the higher net margin — 40.8% vs 2.2%, a 38.7% gap on every dollar of revenue. On growth, EXELIXIS, INC. posted the faster year-over-year revenue change (5.6% vs 2.5%). EXELIXIS, INC. produced more free cash flow last quarter ($332.4M vs $28.9M). Over the past eight quarters, EXELIXIS, INC.'s revenue compounded faster (18.7% CAGR vs 0.9%).
Exelixis, Inc. is a genomics-based drug discovery company located in Alameda, California, and the producer of Cometriq, a treatment approved by the U.S. Food and Drug Administration (FDA) for medullary thyroid cancer with clinical activity in several other types of metastatic cancer.
ScanSource, Inc. is a leading global specialty technology distributor offering a broad portfolio of solutions including point-of-sale systems, barcode scanning tools, cybersecurity products, cloud services and communication solutions. It primarily serves value-added resellers, managed service providers and enterprise clients across North America, Latin America and Europe, covering retail, healthcare, industrial and public sector core segments.
EXEL vs SCSC — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $598.7M | $766.5M |
| Net Profit | $244.5M | $16.5M |
| Gross Margin | 95.6% | 13.4% |
| Operating Margin | 39.3% | 2.3% |
| Net Margin | 40.8% | 2.2% |
| Revenue YoY | 5.6% | 2.5% |
| Net Profit YoY | 74.8% | -3.3% |
| EPS (diluted) | $0.89 | $0.75 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $598.7M | — | ||
| Q4 25 | $597.8M | $766.5M | ||
| Q3 25 | $568.3M | $739.6M | ||
| Q2 25 | $555.4M | $812.9M | ||
| Q1 25 | $566.8M | $704.8M | ||
| Q4 24 | — | $747.5M | ||
| Q3 24 | $539.5M | $775.6M | ||
| Q2 24 | $637.2M | $746.1M |
| Q1 26 | $244.5M | — | ||
| Q4 25 | $193.6M | $16.5M | ||
| Q3 25 | $184.8M | $19.9M | ||
| Q2 25 | $159.6M | $20.1M | ||
| Q1 25 | $139.9M | $17.4M | ||
| Q4 24 | — | $17.1M | ||
| Q3 24 | $118.0M | $17.0M | ||
| Q2 24 | $226.1M | $16.1M |
| Q1 26 | 95.6% | — | ||
| Q4 25 | 96.9% | 13.4% | ||
| Q3 25 | 96.6% | 14.5% | ||
| Q2 25 | 96.5% | 12.9% | ||
| Q1 25 | 96.5% | 14.2% | ||
| Q4 24 | — | 13.6% | ||
| Q3 24 | 96.8% | 13.1% | ||
| Q2 24 | 97.2% | 13.0% |
| Q1 26 | 39.3% | — | ||
| Q4 25 | 39.6% | 2.3% | ||
| Q3 25 | 37.6% | 3.5% | ||
| Q2 25 | 33.6% | 3.3% | ||
| Q1 25 | 28.8% | 3.2% | ||
| Q4 24 | — | 2.5% | ||
| Q3 24 | 25.2% | 2.3% | ||
| Q2 24 | 43.3% | 2.9% |
| Q1 26 | 40.8% | — | ||
| Q4 25 | 32.4% | 2.2% | ||
| Q3 25 | 32.5% | 2.7% | ||
| Q2 25 | 28.7% | 2.5% | ||
| Q1 25 | 24.7% | 2.5% | ||
| Q4 24 | — | 2.3% | ||
| Q3 24 | 21.9% | 2.2% | ||
| Q2 24 | 35.5% | 2.2% |
| Q1 26 | $0.89 | — | ||
| Q4 25 | $0.69 | $0.75 | ||
| Q3 25 | $0.65 | $0.89 | ||
| Q2 25 | $0.55 | $0.87 | ||
| Q1 25 | $0.47 | $0.74 | ||
| Q4 24 | — | $0.70 | ||
| Q3 24 | $0.40 | $0.69 | ||
| Q2 24 | $0.77 | $0.66 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.1B | $83.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $2.2B | $910.9M |
| Total Assets | $2.8B | $1.7B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $1.1B | — | ||
| Q4 25 | $988.5M | $83.5M | ||
| Q3 25 | $791.1M | $124.9M | ||
| Q2 25 | $1.0B | $126.2M | ||
| Q1 25 | $1.1B | $146.3M | ||
| Q4 24 | — | $110.5M | ||
| Q3 24 | $1.2B | $145.0M | ||
| Q2 24 | $1.0B | $185.5M |
| Q1 26 | $2.2B | — | ||
| Q4 25 | $2.2B | $910.9M | ||
| Q3 25 | $2.0B | $914.0M | ||
| Q2 25 | $2.1B | $906.4M | ||
| Q1 25 | $2.2B | $901.7M | ||
| Q4 24 | — | $900.7M | ||
| Q3 24 | $2.3B | $920.9M | ||
| Q2 24 | $2.1B | $924.3M |
| Q1 26 | $2.8B | — | ||
| Q4 25 | $2.8B | $1.7B | ||
| Q3 25 | $2.7B | $1.7B | ||
| Q2 25 | $2.8B | $1.8B | ||
| Q1 25 | $2.9B | $1.7B | ||
| Q4 24 | — | $1.7B | ||
| Q3 24 | $3.0B | $1.8B | ||
| Q2 24 | $2.8B | $1.8B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $333.5M | $30.8M |
| Free Cash FlowOCF − Capex | $332.4M | $28.9M |
| FCF MarginFCF / Revenue | 55.5% | 3.8% |
| Capex IntensityCapex / Revenue | 0.2% | 0.3% |
| Cash ConversionOCF / Net Profit | 1.36× | 1.87× |
| TTM Free Cash FlowTrailing 4 quarters | $875.8M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $333.5M | — | ||
| Q4 25 | $290.3M | $30.8M | ||
| Q3 25 | $49.0M | $23.2M | ||
| Q2 25 | $211.4M | — | ||
| Q1 25 | $240.3M | $66.1M | ||
| Q4 24 | — | $-6.2M | ||
| Q3 24 | $271.3M | $44.8M | ||
| Q2 24 | $119.5M | — |
| Q1 26 | $332.4M | — | ||
| Q4 25 | $288.8M | $28.9M | ||
| Q3 25 | $46.2M | $20.8M | ||
| Q2 25 | $208.5M | — | ||
| Q1 25 | $236.3M | $64.6M | ||
| Q4 24 | — | $-8.2M | ||
| Q3 24 | $263.1M | $42.5M | ||
| Q2 24 | $113.0M | — |
| Q1 26 | 55.5% | — | ||
| Q4 25 | 48.3% | 3.8% | ||
| Q3 25 | 8.1% | 2.8% | ||
| Q2 25 | 37.5% | — | ||
| Q1 25 | 41.7% | 9.2% | ||
| Q4 24 | — | -1.1% | ||
| Q3 24 | 48.8% | 5.5% | ||
| Q2 24 | 17.7% | — |
| Q1 26 | 0.2% | — | ||
| Q4 25 | 0.2% | 0.3% | ||
| Q3 25 | 0.5% | 0.3% | ||
| Q2 25 | 0.5% | 0.3% | ||
| Q1 25 | 0.7% | 0.2% | ||
| Q4 24 | — | 0.3% | ||
| Q3 24 | 1.5% | 0.3% | ||
| Q2 24 | 1.0% | 0.2% |
| Q1 26 | 1.36× | — | ||
| Q4 25 | 1.50× | 1.87× | ||
| Q3 25 | 0.27× | 1.17× | ||
| Q2 25 | 1.32× | — | ||
| Q1 25 | 1.72× | 3.79× | ||
| Q4 24 | — | -0.36× | ||
| Q3 24 | 2.30× | 2.64× | ||
| Q2 24 | 0.53× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
EXEL
| Cabometyx | $544.7M | 91% |
| Collaboration | $52.1M | 9% |
| Collaborative Arrangementwith Takeda | $5.9M | 1% |
| Cometriq | $1.8M | 0% |
SCSC
| Products And Services | $723.4M | 94% |
| Intelisys Advisory | $25.0M | 3% |
| Recurring Revenue | $18.2M | 2% |
